130 related articles for article (PubMed ID: 35297649)
1. Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice.
Schröder C; Gower-Page C; Reyes-Rivera I; Patel A; Price R; Sen S; Davies J; Castellanos E; Snider J; Bai X; Fisher V; Mhatre SK
JCO Clin Cancer Inform; 2022 Mar; 6():e2100133. PubMed ID: 35297649
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab Plus Trastuzumab for Treatment-Refractory
Narita Y; Yoshimoto T; Namai T; Asakawa T; Kawakami S; Gower-Page C; Reyes-Rivera I; Patel A; Nakamura Y
JCO Clin Cancer Inform; 2022 May; 6():e2200022. PubMed ID: 35649212
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.
Strickler JH; Hsu LI; Wright P; Stecher M; Siadak MF; Palanca-Wessels MC; Yu J; Zhang N; Espenschied CR; Lang K; Bekaii-Saab TS
J Natl Compr Canc Netw; 2023 Aug; 21(8):805-812.e1. PubMed ID: 37549907
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment.
Yang L; Li W; Lu Z; Lu M; Zhou J; Peng Z; Zhang X; Wang X; Shen L; Li J
BMC Cancer; 2022 Apr; 22(1):355. PubMed ID: 35365123
[TBL] [Abstract][Full Text] [Related]
6. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
[TBL] [Abstract][Full Text] [Related]
7. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.
Fakih M; Tu H; Hsu H; Aggarwal S; Chan E; Rehn M; Chia V; Kopetz S
Oncologist; 2022 Aug; 27(8):663-674. PubMed ID: 35472176
[TBL] [Abstract][Full Text] [Related]
8. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis.
Gao M; Jiang T; Li P; Zhang J; Xu K; Ren T
Pharmacol Res; 2022 Aug; 182():106330. PubMed ID: 35781058
[TBL] [Abstract][Full Text] [Related]
10. Validation of
Raghav K; Loree JM; Morris JS; Overman MJ; Yu R; Meric-Bernstam F; Menter D; Korphaisarn K; Kee B; Muranyi A; Singh S; Routbort M; Chen K; Shaw KRM; Katkhuda R; Shanmugam K; Maru D; Fakih M; Kopetz S
JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100667
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
12. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
De Cuyper A; Van Den Eynde M; Machiels JP
Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
[TBL] [Abstract][Full Text] [Related]
13. Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study.
Chang J; Xu M; Wang C; Huang D; Zhang Z; Chen Z; Zhu X; Li W
Clin Colorectal Cancer; 2022 Dec; 21(4):347-353. PubMed ID: 35941028
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
Sawada K; Nakamura Y; Yamanaka T; Kuboki Y; Yamaguchi D; Yuki S; Yoshino T; Komatsu Y; Sakamoto N; Okamoto W; Fujii S
Clin Colorectal Cancer; 2018 Sep; 17(3):198-205. PubMed ID: 29866615
[TBL] [Abstract][Full Text] [Related]
15. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer.
Yagisawa M; Sawada K; Nakamura Y; Fujii S; Yuki S; Komatsu Y; Yoshino T; Sakamoto N; Taniguchi H
Clin Colorectal Cancer; 2021 Jun; 20(2):113-120.e1. PubMed ID: 33384243
[TBL] [Abstract][Full Text] [Related]
18. Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes.
Jang JY; Jeon YK; Jeong SY; Lim SH; Park YS; Lim HY; Lee JY; Kim ST
J Gastrointest Oncol; 2023 Oct; 14(5):2097-2110. PubMed ID: 37969818
[TBL] [Abstract][Full Text] [Related]
19. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
[TBL] [Abstract][Full Text] [Related]
20. Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab.
Liu R; Zhao X; Guo W; Huang M; Qiu L; Zhang W; Zhang Z; Li W; Zhu X; Chen Z
Clin Transl Oncol; 2020 Jun; 22(6):928-934. PubMed ID: 31571151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
